<DOC>
	<DOCNO>NCT02910466</DOCNO>
	<brief_summary>Chronic hypoparathyroidism life-long disease chronic administration rhPTH ( 1-84 ) potential treatment option . The group subject AAAE0544 core study take rhPTH ( 1-84 ) treatment hypoparathyroidism 11 year . This study design extend experience gain knowledge safe effective rhPTH ( 1-84 ) patient hypoparathyroidism long-term duration .</brief_summary>
	<brief_title>Extended Use Recombinant Human Parathyroid Hormone ( rhPTH ( 1-84 ) ) Hypoparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Hypoparathyroidism</mesh_term>
	<criteria>1 . Subjects currently previously enrol core study ( AAAE0544 ) maintain uninterrupted therapy rhPTH ( 184 ) ( transient interruption 1 month continuously treatment may allow ) . 2 . Signed date informed consent form ( ICF ) . 3 . Adult men woman 18 85 year age . 4 . History hypoparathyroidism least 12 month prior rhPTH ( 184 ) treatment , define requirement supplemental calcium and/or active vitamin D maintain serum calcium along undetectable insufficient Parathyroid hormone ( PTH ) concentration . 5 . Able perform daily subcutaneous selfinjections study medication ( designee perform injection ) . 6 . Willingness ability understand comply protocol . Women must agree pregnancy test acceptable method contraception , detail protocol . 1 . The subject treat treated investigational drug , aside rhPTH ( 184 ) , within 30 day consent . 2 . As assessed investigator , subject safety medical issue contraindicate participation study . 3 . The subject and/or subject 's parent ( ) legallyauthorized representative ( ) unable understand nature , scope , possible consequence study . 4 . The subject unable comply protocol , eg , uncooperative protocol schedule , refusal agree study procedure , inability return evaluation , otherwise unlikely complete study , determine investigator medical monitor . 5 . The subject pregnant lactating . 6 . Subjects increase baseline risk osteosarcoma subject Paget 's disease bone unexplained elevation alkaline phosphatase , subject hereditary disorder predispose osteosarcoma subject prior history external beam implant radiation therapy involve skeleton .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>